Advertisement

American Journal of Cardiovascular Drugs

, Volume 19, Issue 2, pp 219–221 | Cite as

Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”

  • Prashant B. RanaEmail author
  • Nilan T. Jacob
  • Tomson Toms
  • Shraddha Bhure
Letter to the editor
  • 64 Downloads

Dear Editors,

In a recent issue of the American Journal of Cardiovascular Drugs, Ramakrishnan et al. [1] published their research on the efficacy and safety of bolus intravenous tenecteplase (TNK-tPA) in patients with acute ischemic stroke (AIS) arriving within 3 h of symptom onset. The authors conducted two open-label studies enrolling a total of 112 patients with AIS arriving within 3 h of onset of symptoms. Study 1 was an open-label randomized dose-finding preliminary study enrolling 50 eligible patients in which an intravenous bolus of TNK-tPA 0.1 mg/kg (20 patients) or 0.2 mg/kg (30 patients) was administered. Study 2 was a single-arm, open-label study enrolling 62 eligible patients in which an intravenous bolus of TNK-tPA 0.2 mg/kg was administered. The primary endpoint of both studies was an improvement of ≥ 8 points or a score of 0 on the National Institutes of Health Stroke Scale (NIHSS) (major neurological improvement) at 24 h. However, in study 2, for comparison with...

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to assist with the preparation of this manuscript.

Conflicts of interest

Prashant Rana, Nilan Jacob, Tomson Toms, and Shraddha Bhure are employees of Boehringer Ingelheim India Pvt. Ltd., and have no additional conflicts of interest that might be relevant to the content of this letter.

References

  1. 1.
    Ramakrishnan TCR, Kumaravelu S, Narayan SK, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials. Am J Cardiovasc Drugs. 2018;18(5):387–95.CrossRefGoogle Scholar
  2. 2.
    Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28:1936–41.CrossRefGoogle Scholar
  3. 3.
    Arboix A, Alio J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150–61.CrossRefGoogle Scholar
  4. 4.
    Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707–11.CrossRefGoogle Scholar
  5. 5.
    Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.CrossRefGoogle Scholar
  6. 6.
    Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.CrossRefGoogle Scholar
  7. 7.
    Campbell BC, et al. Tenecteplase versus Alteplase before thrombectomy for ischaemic stroke. N Engl J Med. 2018;378:1573–82.CrossRefGoogle Scholar
  8. 8.
    Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.CrossRefGoogle Scholar
  9. 9.
    Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–110.CrossRefGoogle Scholar
  10. 10.
    Hill MD et al. A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2). https://clinicaltrials.gov/ct2/show/NCT02398656. Accessed 27 Sep 2018.
  11. 11.
    Spratt N et al. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363714&isReview=true. Accessed 27 Sep 2018.
  12. 12.
    Mathiesen EB et al. Tenecteplase in wake-up ischaemic stroke trial (TWIST). https://clinicaltrials.gov/ct2/show/NCT03181360. Accessed 27 Sep 2018.
  13. 13.
    Muir K et al. Alteplase–tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST-2). https://clinicaltrials.gov/ct2/show/NCT02814409. Accessed 27 Sep 2018.
  14. 14.
    Campbell B, Sallaberger M et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischaemic stroke (EXTEND-IA TNK Part 2). https://clinicaltrials.gov/ct2/show/NCT03340493. Accessed 27 Sep 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Prashant B. Rana
    • 1
    Email author
  • Nilan T. Jacob
    • 1
  • Tomson Toms
    • 1
  • Shraddha Bhure
    • 1
  1. 1.Boehringer Ingelheim India Pvt. LtdMumbaiIndia

Personalised recommendations